ArticleBMC cancer2025
Gem-TIP as a salvage therapy for pediatric extracranial malignant rhabdoid tumors: insights from a retrospective case series.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis retrospective case series aimed to provide initial insights into the potential effectsof Gemcitabine (Gem), Nab-paclitaxel, Ifosfamide, and Cisplatin (Gem-TIP) combination therapy in children with relapsed/progressive extracranial malignant rhabdoid tumors (eMRTs).
methodsA retrospective review of patients treated with Gem-TIP following relapse/progression was conducted. Radiologic responses were assessed using RECIST 1.1 criteria, with supplemental imaging data provided for detailed evaluation. Details of concurrent therapies, including radiotherapy, were documented to better delineate their influence on treatment outcomes.
resultsTen patients were included, with a median age of 29.5 months at diagnosis. Tumor origins were predominantly renal (8 cases). Patients received a median of 3.1 cycles of Gem-TIP. The overall response rate (ORR) was 40% (1 CR, 3 PR), and the disease control rate (DCR) was 70%. Median event-free survival (EFS) and overall survival (OS) were 4 and 7.5 months, respectively. Radiotherapy and secondary surgery administered to 3 patients after Gem-TIP chemotherapy, likely contributed to improved local control. Toxicities included grade 4 neutropenia (50%) and thrombocytopenia (70%). However, limited data on hearing evaluation due to the retrospective design was noted.
conclusionsGem-TIP chemotherapy demonstrated preliminary evidence of therapeutic activity in relapsed/progressive eMRTs, but its role requires to be verified by large, prospective multi-center studies of rigorous design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.